TDC
EVFM

Thompson Davis & Co’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Thompson Davis & Co’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-67
Closed -$3K – 811
2018
Q2 		$3K Buy
+67
New +$5.27K 0.01% 593

Other funds holding EVFM

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IA
Independence Advisors Wayne, Pennsylvania $466M AUM 11.32% 1-Year Est. Return

Thompson Davis & Co's EVFM Position: Q3 2018 in Review

Thompson Davis & Co sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2018, closing a stake of 67 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in EVFM in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 16 funds tracked by Wall St. Rank hold EVFM as of Q3 2018.

  • Thompson Davis & Co reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 67 Evofem Biosciences, Inc. Common Stock shares in Q3 2018, an estimated $3K.
  • Thompson Davis & Co first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Evofem Biosciences, Inc. Common Stock position peaked at $3K in Q2 2018.
  • 16 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.